Table 2.

Baseline and postintervention assessment of serum total and bioavailable estradiol and testosterone, SHBG, progesterone, IGF-1, IGFBP3, and CRP

Variable or biomarkerBaselinePostinterventionDifferenceP value (Wilcoxon)
SHBG, nmol/L68 (26–241)106 (38–274)31 (−5 to 65)0.0001
Estradiol, pg/mL54 (24–458)107 (43–914)56 (−5 to 752)0.0001
Estradiol, nmol/L0.2 (0.1–1.7)0.4 (0.2–3.4)0.2 (0.0–2.8)
Bioavailable estradiol, pmol/L2.7 (0.7–23.2)3.6 (1.5–19.7)1.3 (−8.8 to 12.3)0.0001
Testosterone, ng/mL1.29 (0.50–12.11)1.07 (0.42–7.39)−0.12 (−5.78 to 2.27)0.029
Testosterone, nmol/L4.5 (1.7–42)3.7 (1.5–25.7)−0.4 (−20 to 7.9)
Bioavailable testosterone, pmol/L43 (13–802)27 (10–213)−17 (−588 to 25)0.0001
Progesterone, ng/mL0.33 (0.17–11.81)0.26 (0.07–5.92)−0.09 (−7.09 to 1.17)0.0058
IGF-I, ng/mL109 (60–184)87 (50–128)−17 (−101 to 25)0.0001
IGF-I, nmol/L14 (8–24)11 (7–17)−2 (−13 to 3)
IGFBP-3, ng/mL2,153 (1,582–2,944)2,052 (1,402–2,937)−48 (−597 to 276)0.024
IGFBP-3, nmol/L75 (55–103)72 (49–103)−1.5 (−20 to 10)
IGF-I:IGFBP-3 molar ratio0.19 (0.13–0.32)0.16 (0.10–0.26)−0.03 (−0.1 to 0.05)0.0002
CRP, μg/mL1.5 (0.1–7.7)1.4 (0.1–8.4)−0.04 (−4.1 to 4.8)0.79
  • NOTE: Median (range) values are provided for 27 subjects with paired specimens.